Compare MASS & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MASS | ACRS |
|---|---|---|
| Founded | 2012 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 498.1M | 529.9M |
| IPO Year | 2020 | 2015 |
| Metric | MASS | ACRS |
|---|---|---|
| Price | $9.33 | $3.33 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 12 |
| Target Price | ★ $14.00 | $10.27 |
| AVG Volume (30 Days) | 364.9K | ★ 2.7M |
| Earning Date | 11-10-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 125.47 | 69.01 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $56,197,000.00 | $1,683,000.00 |
| Revenue This Year | $23.13 | N/A |
| Revenue Next Year | $18.66 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.03 | $2.34 |
| 52 Week High | $13.35 | $6.60 |
| Indicator | MASS | ACRS |
|---|---|---|
| Relative Strength Index (RSI) | 36.12 | 36.10 |
| Support Level | $6.20 | $3.24 |
| Resistance Level | $11.16 | $3.44 |
| Average True Range (ATR) | 0.90 | 0.28 |
| MACD | -0.24 | 0.00 |
| Stochastic Oscillator | 5.66 | 4.02 |
908 Devices Inc develops a suite of purpose-built handheld devices for point-of-need chemical analysis. Leveraging mass spectrometry, optical spectroscopy, analytics and machine learning technologies, the company makes devices that are smaller and more accessible than conventional laboratory instruments. Its devices, including MX908, ThreatID, XplorIR and VipIR, are used to analyze unknown materials and provide actionable answers in health, safety and defense technology applications, addressing the fentanyl and illicit drug crisis, toxic carcinogen exposure and security threats. The company reimagines mass spectrometry technology by developing smaller, lower-cost and simpler-to-operate devices compared to conventional instruments, and generates maximum revenue from the United States.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.